Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Harvard Business School
Chubb
Cipla
Mallinckrodt
Daiichi Sankyo
Queensland Health
Citi
Dow

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESKALITH

« Back to Dashboard

Clinical Trials for Eskalith

Trial ID Title Status Sponsor Phase Summary
NCT00057681 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed National Institute of Mental Health (NIMH) Phase 3 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00057681 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed Washington University School of Medicine Phase 3 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00221975 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling Completed University Hospitals Cleveland Medical Center Phase 3 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients begin treatment with a combination of lithium and divalproex. Once these medications are tolerated, they are randomly assigned to double-blind treatment with lamotrigine or placebo. Patients remain in this study until they experience a marked bimodal response for four consecutive weeks. This study is sponsored by the Stanley Foundation.
NCT00601575 Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions Completed Roxane Laboratories N/A The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fed conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Eskalith

Condition Name

Condition Name for Eskalith
Intervention Trials
Bipolar Disorder 6
Bipolar Affective Disorder 1
Treatment Resistant Depression 1
Major Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eskalith
Intervention Trials
Bipolar Disorder 7
Depression 2
Disease 2
Depressive Disorder, Major 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eskalith

Trials by Country

Trials by Country for Eskalith
Location Trials
United States 22
Canada 2
Sweden 2
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eskalith
Location Trials
Ohio 3
Pennsylvania 3
California 2
Arkansas 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eskalith

Clinical Trial Phase

Clinical Trial Phase for Eskalith
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eskalith
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eskalith

Sponsor Name

Sponsor Name for Eskalith
Sponsor Trials
Washington University School of Medicine 2
Roxane Laboratories 2
University Hospitals Cleveland Medical Center 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eskalith
Sponsor Trials
Other 9
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Accenture
Colorcon
Johnson and Johnson
Dow
Healthtrust
Citi
Fish and Richardson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.